Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus
Arch. endocrinol. metab. (Online)
;
66(6): 868-870, Nov.-Dec. 2022.
Article
in English
|
LILACS-Express
| LILACS
| ID: biblio-1403249
ABSTRACT
"What's in a name? That which we call a rose / By any other name would smell as sweet" (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare's implication is that a name is nothing but a word and it therefore represents a convention with no intrinsic meaning. Whilst this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rational for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology and endocrine pediatric societies now proposes changing the name of "diabetes insipidus" to "Arginine Vasopressin Deficiency (AVP-D)" for central etiologies, and "Arginine Vasopressin Resistance (AVP-R)" for nephrogenic etiologies This editorial provides both the historical context and the rational for this proposed name change.
Full text:
Available
Index:
LILACS (Americas)
Language:
English
Journal:
Arch. endocrinol. metab. (Online)
Journal subject:
Endocrinology
/
Metabolism
Year:
2022
Type:
Article
Affiliation country:
Australia
/
Brazil
/
Japan
/
Switzerland
/
United States
/
United kingdom
Institution/Affiliation country:
Georgetown University/US
/
Nagoya University Graduate School of Medicine/JP
/
Newcastle University/GB
/
Non-executive Director Pituitary Foundation/GB
/
St Vincents Hospital/AU
/
Universidade Federal de Minas Gerais/BR
/
University Hospital and University of Basel/CH
/
University Hospitals of Leicester NHS Trust/GB
/
University of Cambridge & Addenbrookes Hospital/GB
/
University of Oxford/GB
Similar
MEDLINE
...
LILACS
LIS